期刊
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
卷 11, 期 8, 页码 1925-1938出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2015.07.012
关键词
Cremophor-EL; Taxol (R); Paclitaxel; Abraxane (R); Interleukin 8; Oxidative stress; Cytokines; Immunotoxicity
资金
- Frederick National Laboratory for Cancer Research, National Institutes of Health [HHSN261200800001E]
Understanding the ability of cytotoxic oncology drugs, and their carriers and formulation excipients, to induce pro-inflammatory responses is important for establishing safe and efficacious formulations. Literature data about cytokine response induction by the traditional formulation of paclitaxel, Taxol (R), are controversial, and no data are available about the pro-inflammatory profile of the nano-albumin formulation of this drug, Abraxane (R). Herein, we demonstrate and explain the difference in the cytokine induction profile between Taxol (R) and Abraxane (R), and describe a novel mechanism of cytokine induction by a nanosized excipient, Cremophor EL, which is not unique to Taxol (R) and is commonly used in the pharmaceutical industry for delivery of a wide variety of small molecular drugs. From the Clinical Editor: Advances in nanotechnology have enabled the production of many nano-formulation drugs. The cellular response to drugs has been reported to be different between traditional and nano-formulations. In this article, the authors investigated and compared cytokine response induction profiles between Taxol (R) and Abraxane (R). The findings here provided further understanding to create drugs with better safety profiles. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据